Events

Home Events

02

Dec2016

PMPRB’s Phase 1 of Rethinking the Guidelines Public Comments Now Available

/ PMPRB, What's New
As a first step to framework modernization, the Patented Medicines Prices Review Board (PMPRB) is undertaking major consultations regarding possible ... Read More

01

Dec2016

Alberta Changes Special Authorization Criteria for Coverage of INFLECTRA™ (infliximab)

/ Alberta, What's New
Effective December 1, 2016, all new Special Authorization requests for the treatment of Moderately to Severely Active Crohn's Disease and ... Read More

28

Nov2016

Ontario Public Drug Programs Funds New Indications for INFLECTRA™ (infliximab)

/ Ontario, pCPA, What's New
Effective November 30, 2016, the Ontario Public Drug Programs will begin funding INFLECTRA™ (infliximab) as a limited use benefit for ... Read More

23

Nov2016

PMPRB Vice Chair Re-appointed

/ PMPRB, What's New
The Patented Medicine Prices Review Board (PMPRB) announced the reappointment of Dr. Mitchell Levine of Hamilton, Ontario as Vice-chairperson of ... Read More

31

Oct2016

Registration is Open for CAHR’s 6th Annual National Day

/ CAHR, What's New
The Canadian Association for Healthcare Reimbursement (CAHR) is holding a one-day event to explore a national approach to pharma policy ... Read More

20

Oct2016

INESSS Manufacturer Appointments

/ INESSS, Quebec, What's New
INESSS Upcoming Meetings with Manufacturers – June 2017 “Liste des médicaments” INESSS is offering an opportunity for in-person meetings to manufacturers ... Read More

13

Oct2016

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

/ pCPA, What's New
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2016: ... Read More

11

Oct2016

Application of Generic Substitution to the Exceptional Access Program (EAP)

/ Ontario, What's New
Effective November 1, 2016, the ministry is introducing the application of generic substitution to the Exceptional Access Program (EAP). Under this ... Read More